Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H10N4O2 |
Molecular Weight | 194.1906 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N
InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
Molecular Formula | C8H10N4O2 |
Molecular Weight | 194.1906 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:53 UTC 2023
by
admin
on
Fri Dec 15 15:20:53 UTC 2023
|
Record UNII |
3G6A5W338E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV04CG30
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NDF-RT |
N0000175729
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
CFR |
21 CFR 340.10
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NDF-RT |
N0000175790
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
WHO-VATC |
QN06BC01
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NCI_THESAURUS |
C54060
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NDF-RT |
N0000175739
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
IARC | Caffeine | ||
|
NDF-RT |
N0000008118
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
NDF-RT |
N0000008118
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
DSLD |
367 (Number of products:3156)
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
FDA ORPHAN DRUG |
367512
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
EPA PESTICIDE CODE |
660
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
WHO-ATC |
V04CG30
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
FDA ORPHAN DRUG |
31288
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
WHO-ATC |
N06BC01
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
LIVERTOX |
NBK559835
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
||
|
CFR |
21 CFR 340.50
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Caffeine
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
D002110
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
1886
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | RxNorm | ||
|
3G6A5W338E
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
407
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
CAFFEINE
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | Description: Silky, colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in 60 parts of water and in 100 parts of ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Central nervous stimulant. Storage: Caffeine should be kept in a well-closed container. Labelling: The designation on the container of Caffeine should state whether the substance is the monohydrate or is in the anhydrous form. Additional information: Caffeine monohydrate is efflorescent in air. Definition: Caffeine contains not less than 98.5% and not more than 101.0% of C8H10N4O2, calculated with reference to the dried substance. | ||
|
463
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
1086006
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
ALTERNATIVE | |||
|
DB00201
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
CHEMBL113
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
35
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
2519
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
CAFFEINE
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
1085003
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
C328
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
DTXSID0020232
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
27732
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
SUB26077
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
200-362-1
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
5036
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
347
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
SUB13146MIG
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
58-08-2
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
m2909
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | Merck Index | ||
|
3G6A5W338E
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY | |||
|
100000089693
Created by
admin on Fri Dec 15 15:20:53 UTC 2023 , Edited by admin on Fri Dec 15 15:20:53 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->WEAK INHIBITOR |
Nonselective adenosine receptor antagonist
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> INDUCER |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Secondary metabolite detected in developing cacao seeds.
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->WEAK INHIBITOR |
Nonselective adenosine receptor antagonist. May be responsible for pain relief.
Ki
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Human, oral
IN-VITRO
URINE
|
||
|
PARENT -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
MAIN PRIMARY METABOLITE; METABOLISM OCCURS IN LIVER
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.66.pdf
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Cmax | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
|
|||